The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review
Open accessAbstract
Moderate alcohol consumption in patients with nonalcoholic fatty liver disease (NAFLD) is common, yet the effects on cardiovascular and liver health are unclear. Moderate alcohol use is associated with improved insulin sensitivity and decreased cardiovascular mortality in the general population, but whether similar benefits would be observed in persons with NAFLD remains largely unstudied. There is significant overlap in the pathogenesis of alcoholic liver disease (ALD) and NAFLD, although studies of ALD have focused on pathological alcohol intake and few mechanistic studies of moderate alcohol use in NAFLD exist. We undertook a critical review of the effect of moderate alcohol use on cardiovascular and liver disease in patients with NAFLD. A total of seven observational studies met the criteria for inclusion (one for cardiovascular endpoints and six for liver endpoints). Insufficient studies have assessed the association of moderate alcohol use with cardiovascular outcomes. There was a positive association between moderate alcohol use and decreased NASH and fibrosis; however, heavy episodic drinking may accelerate fibrosis progression and moderate alcohol use may increase the risk of hepatocellular carcinoma in patients with advanced fibrosis. Significant methodological limitations were present, including incomplete adjustment for confounding factors and failure to measure lifetime use or the pattern of alcohol intake. Thus, a strong recommendation of benefit of moderate alcohol use in NAFLD cannot be made. There remains a need for additional high-quality longitudinal studies that evaluate both cardiovascular and liver outcomes among NAFLD patients with moderate or lesser degrees of alcohol use. (Hepatology 2017;65:2090-2099).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Table 8. Factors associated with a higher risk of HCC occurrence in MASLD.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [533]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SAUNDERS, J. B., AASLAND, O. G., BABOR, T. F., DE LA FUENTE, J. R., & GRANT, M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02093.x · Cited by 13,597 · cited 1×
“Measurement of alcohol use with standardized and validated questionnaires (42, 43) brings a higher level of rigor to the measurement and facilitates comparisons across studies.”
BackgroundPrevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Kanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682
Williams, C. D., Stengel, J. Z., Asike, M., Torres, D. M., Shaw, J. C., Contreras, M., Landt, C. L., & Harrison, S. A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,182
Self-citationZhu, L., Baker, S. S., Gill, C., Liu, W., Alkhouri, R., Baker, R. D., & Gill, S. R. (2013) · Hepatology · doi:10.1002/hep.26093 · Cited by 1,708 · cited 1×
“In fact, patients with nonalcoholic steatohepatitis (NASH) have increased microbiome-mediated endogenous alcohol production compared to obese and healthy controls.((29)) Moderate alcohol use is associated with small intestinal bacterial overgrowth compared to teetotalers.”
BackgroundDixon, J. B., Bhathal, P. S., & O’Brien, P. E. (2001) · Gastroenterology · doi:10.1053/gast.2001.25540 · Cited by 1,369
Alcohol consumption and mortality among middle-aged and elderly U.S. adults
Thun, M. J., Peto, R., Lopez, A. D., Monaco, J. H., Henley, S. J., Heath, C. W., & Doll, R. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712113372401 · Cited by 1,313
Ascha, M. S., Hanouneh, I. A., Lopez, R., Tamimi, T. A.-R., Feldstein, A. F., & Zein, N. N. (2010) · Hepatology · doi:10.1002/hep.23527 · Cited by 1,296
Kozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–137 of 137
Zhang, N., Li, J., Xie, X., Hu, Y., Chen, H., Zhang, Y., Liu, Y., Zhu, X., Xu, H., Wang, Z., et al. (2025) · BMC Public Health · doi:10.1186/s12889-025-21752-1 · Cited by 3
Foog, D. H.-S., Kwok, D., Yu, B., & Wong, V. (2017) · Current Hepatology Reports · doi:10.1007/s11901-017-0376-4 · Cited by 6
Sogabe, M., Okahisa, T., Kagawa, M., Kashihara, T., Fujmoto, S., Kawaguchi, T., Yokoyama, R., Kagemoto, K., Tanaka, H., Kida, Y., et al. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14221 · Cited by 3
Assessment of liver disease in patients with chronic hepatitis C and unhealthy alcohol use
Fuster, D., García‐Calvo, X., Zuluaga, P., Bolao, F., & Muga, R. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i23.3223 · Cited by 3
Liang, Z., Jin, H., Gao, W., Zhang, H., Hu, X., Li, R., Li, X., Cheng, Y., Guo, L., & Liu, Y. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00677 · Cited by 2
Integrating Alcohol Use Into MASLD Care: A Practical Guide for Diabetes and Obesity Care Teams
Alexopoulos, A., & Cusi, K. J. (2026) · Diabetes Care · doi:10.2337/dci26-0019 · Cited by 2
Non-alcoholic fatty liver disease: an epigenetic view of pathogenesis and a new treatment options
Айтбаев, К. А., Murkamilov, I. T., Абдилалимовна, М. Ж., Fomin, V. V., Kudaibergenova, I., & Yusupov, F. A. (2022) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-203-7-171-176 · Cited by 2
Gautam, S. (2018) · Journal of Clinical Epigenetics · doi:10.21767/2472-1158.100086 · Cited by 2
Advice Regarding Alcohol Use by Individuals With Nonalcoholic Fatty Liver Disease: Primum non nocere
Dunn, W., & Chalasani, N. (2018) · Hepatology · doi:10.1002/hep.30245 · Cited by 2
Liu, Z., Zhang, X., & Chen, X. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.018 · Cited by 2
Ayyed, M. F., Hussein, F. F., & Mohammed, M. J. (2024) · IOP Conference Series Earth and Environmental Science · doi:10.1088/1755-1315/1371/6/062022 · Cited by 1
Transitioning from NAFLD to MAFLD and MASLD: the toxic relationship with alcohol consumption
Özercan, M., Tawheed, A., & El‐Kassas, M. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001273 · Cited by 1
Lee, J.-H., Ryu, H. E., Han, T., Park, B., Heo, S., & Kwon, Y. (2025) · Endocrine · doi:10.1007/s12020-025-04200-3 · Cited by 1
Yeo, Y. H., Rui, F., Zhu, Y., Xu, X., Ma, X., Ni, W., Sun, Y., Hu, X., Wu, C., Shi, J., et al. (2025) · Portal hypertension & cirrhosis · doi:10.1002/poh2.70015 · Cited by 1
Eldesouki, M. H., Black, A., Amador-Martínez, K., Elnaggar, M. Y., Elfert, K., & Duong, N. K. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100792 · Cited by 1
Metabolic and Alcohol-Associated
Sandella, R., & Rinella, M. E. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.09.003 · Cited by 1
Yang, A., Yan, X., Wang, Y., Han, Q., Tong, X., Chen, S., Zhao, X., Chen, W., Jia, J., Schuppan, D., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001715 · Cited by 1
The effects of binge drinking on healthy and diseased livers
Rumbolt, C., & Minuk, G. Y. (2021) · Canadian Liver Journal · doi:10.3138/canlivj-2020-0037 · Cited by 1
Xiao, J., Ng, C. H., Chan, K. E., Tang, A. S. P., Teh, R., Ling, A. H. Z., Yong, J. N., Lim, W. H., Tan, D. J. H., Tan, C., et al. (2022) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2022.2105168 · Cited by 1
Alcohol Consumption and Nonalcoholic Steatohepatitis/ Nonalcoholic Fatty Liver Disease.
Long, M. T. (2022) · PubMed Central · Cited by 1
Liver Ultrasound Abnormalities in Alcohol Use Disorder
Fuster, D., García‐Calvo, X., Zuluaga, P., Rivas, I., Sanvisens, A., Tor, J., & Muga, R. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85941 · Cited by 1
Prävention der nicht-alkoholischen Steatohepatitis (NASH) und deren Folgeerkrankungen
Huber, Y., & Schattenberg, J. M. (2020) · Springer eBooks · doi:10.1007/978-3-662-58879-6_10 · Cited by 1
On the operational definition of fatty liverPreprint
Bedogni, G., Bonino, F., & Tiribelli, C. (2018) · Qeios · doi:10.32388/420391 · Cited by 1
Gao, B., Xiang, X., Leggio, L., & Koob, G. F. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch53 · Cited by 1
Liver Disease, Nonalcoholic Fatty
Rau, M., & Geier, A. (2020) · Encyclopedia of Gastroenterology · doi:10.1016/b978-0-12-801238-3.65789-6 · Cited by 2
Welchen Einfluss haben Ernährung und Genussmittel auf die Fettleber?
Niederau, C. (2019) · Gastro-News · doi:10.1007/s15036-019-0660-y
Alcohol Consumption in Non-Alcoholic Fatty Liver Disease: Safety and Disease Overlap
Reddy, S. S. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00542-w
Diagnostik und Therapie des hepatozellulären Karzinoms
van Bömmel, F., Denecke, T., Seehofer, D., Schindler, A., Veelken, R., & Berg, T. (2020) · Der Onkologe · doi:10.1007/s00761-020-00858-8
Letter to Niezen and colleagues
Semmler, G., Egger, M., Hefner, E., & Datz, C. (2021) · Liver International · doi:10.1111/liv.15037
Sánchez, C. N. T. (2022) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/59942
Zhang, N., Zhang, Y., Wei, J., Xiang, Y., Hu, Y., & Xiao, X. (2024) · PubMed Central · doi:10.12182/20240560503
NAFLD’s Predisposion: insight from phenome-wide association and Mendelian RandomizationPreprint
Jiang, H., Dai, Q., Yan, H., Du, Q., & Shen, T. (2024) · Research Square · doi:10.21203/rs.3.rs-4722888/v1
Gender-Specific Effects of Smoking Cessation on Drinking: Evidence from a Randomized Trial
Park, H., An, J. D., & Kim, D. (2025) · Journal of Drug Issues · doi:10.1177/00220426251384854
A contemporary review of care gaps in hepatocellular carcinoma surveillance
Duong, N., Nguyen, V., & Nguyen, M. H. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2592105
Additional file 1 of Response to semaglutide of non-drinker subjects with type 2 diabetes
Petralli, G., Raggi, F., Zoppo, A. D., Rovera, C., Salvati, A., Brunetto, M. R., & Solini, A. (2024) · Figshare · doi:10.6084/m9.figshare.25853087
Alkhouri, N., Almomani, A., Le, P., Payne, J. Y., Asaad, I., Sakkal, C., Vos, M., Noureddin, M., & Kumar, P. (2022) · Figshare · doi:10.6084/m9.figshare.20408689
Liu, J., Yamashita, K., & Yamano, S. (2026) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.70154
Metadata
- Authors
- Ajmera, V. H., Terrault, N. A., & Harrison, S. A.
- Affiliations
- University of California, San Francisco (US)
- Brooke Army Medical Center (US)
- Corresponding author
- Ajmera, Veeral H.
- Venue
- Hepatology
- Published
- 2017-04-28
- Volume
- 65
- Issue
- 6
- Pages
- 2090-2099
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- PMC
- PMC5444963
- OpenAlex
- W2573357558
- Cited by
- 137
- References
- 49
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 18 · 2023: 9 · 2022: 16 · 2021: 13 · 2020: 19 · 2019: 22 · 2018: 17 · 2017: 7
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Defense
- National Institute of Diabetes and Digestive and Kidney Diseases (T32 5T32DK060414, T32DK060414)
- U.S. Army Medical Department
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- moderate drinking, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, liver fibrosis, hepatocellular carcinoma, cardiovascular mortality, insulin sensitivity, binge drinking, alcoholic liver disease, alcohol and liver disease
- MeSH terms
- Alcohol Drinking, Biopsy, Needle, Cardiovascular Diseases, Female, Carcinoma, Hepatocellular, Humans, Immunohistochemistry, Liver Diseases, Alcoholic, Liver Neoplasms, Longitudinal Studies, Male, Middle Aged, Prognosis, Severity of Illness Index, Disease Progression, Risk Assessment, Needs Assessment, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
